ROR1 is a receptor tyrosine kinase (RTK) recently identified to be overexpressed at the gene and protein levels in chronic lymphocytic leukemia (CLL). Monoclonal antibodies (MAbs) against RTKs have been successfully applied for therapy of solid tumors. We generated five MAbs against the Ig (n ¼ 1), cysteine-rich (CRD) (n ¼ 2) and kringle (KNG) (n ¼ 2) domains, respectively, of the extracellular part of ROR1. All CLL patients (n ¼ 20) expressed ROR1 on the surface of the leukemic cells. A significantly higher frequency of ROR1 expression was found in patients with progressive versus non-progressive disease, and in those with unmutated versus mutated IgVH genes. All five MAbs alone induced apoptosis in the absence of complement or added effector cells (Annexin-V and MTT, as well as cleavage of poly-(ADP ribose)-polymerase, caspase-8 and caspase-9) of CLL cells but not of normal B cells. Most effective were MAbs against CRD and KNG, significantly superior to rituximab (Po0.005). Cross-linking of anti-ROR1 MAbs using the F(ab 0 ) 2 fragments of anti-Fc antibodies significantly augmented apoptosis. Two of the MAbs induced complement-dependent cytotoxicity (CDC) similar to that of rituximab and one anti-ROR1 MAb (KNG) (IgG1) showed killing activity by antibody-dependent cellular cytotoxicity. The identified ROR1 epitopes may provide a basis for generating human ROR1 MAbs for therapy.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by accumulation of small B-lymphocytes with mature appearance in blood, bone marrow, lymph nodes and other lymphoid tissues. CLL is not necessarily treated at diagnosis, but rather after onset of clinical symptoms. 1 Over the past decades, there has been a transition from single-agent therapy with alkylating compounds to nucleosides, multidrug combinations and chemo-immunotherapy. 2 Immunotherapy includes monoclonal antibodies (MAbs) against CD20 (rituximab, ofatumumab) and CD52 (alemtuzumab) 3 --5 Novel treatment strategies have increased complete remission rates, progression-free survival and overall survival. 6 However, CLL is thought to be largely incurable. 5, 7 Thus, there is an unmet medical need to improve prognosis by developing new effective therapies.
Targeting receptor tyrosine kinases (RTKs) may be achieved not only by small interfering molecules but also by MAbs against membrane-close epitopes such as Her2/neu or epidermal growth factor receptor. MAbs against RTKs have independently or in combination with chemotherapy become standard treatment in various clinical settings. 8, 9 RTK-specific antibodies induce tumor cell death by inhibition of RTK-dependent signaling pathways and/or by immune-mediated effector functions. 8, 10, 11 ROR1/ROR2 is one of 20 families of RTKs. 12 --15 Human ROR1 is located on chromosomal region 1p31.3 (http://www.ensembl.org), a region where chromosomal aberrations are not frequently seen in hematological malignancies. The ROR1 gene has a coding region of 2814 bp, with a predicted 937-amino-acid sequence. The molecular weight of the protein varies between 100 and 130 kDa depending on the glycosylation pattern. ROR1 consists of an extracellular part including an Ig-like domain, a cysteinerich domain (CRD) and a kringle (KNG) domain, as well as an intracellular tyrosine kinase and a proline-rich domain. 16 The ROR1 gene was originally cloned from a neuroblastoma cell line. 17 ROR receptors are cell-surface receptors participating in signaling, cell --cell interaction, proliferation, differentiation and metabolism, and have crucial roles in the embryonic development of various organs and tissues. ROR is evolutionarily highly conserved between species, for example, human, mouse, Drosophila and Caenorhabditis elegans, suggesting important biological functions. 12, 13 The structure of the ROR1 protein suggests that activation of the receptor is induced by homodimerization followed by activation of ROR-family-associated signaling pathways. 12, 13 Recent studies on multiple species have indicated that ROR proteins are Wnt-family receptors.
12 Wnt5a may be a ligand for ROR1 but also other Wntregulatory proteins might bind to the CRD region, which is related to the Wnt-binding domain of Frizzled receptors. 12,13,18 --21 The KNG domains of ROR proteins may also function as recognition modules for Wnt and non-Wnt ligands. 13 ROR1 has recently been reported to be overexpressed on CLL cells compared with normal lymphoid and non-lymphoid tissues.
22 --24 ROR1 may thus represent a potential structure for targeted therapy. In this study, we describe the generation, binding and functional activity of a panel of anti-ROR1 MAbs reactive with CLL cells. The functional epitopes identified may provide a basis for generating human ROR1 MAbs for clinical trials.
MATERIALS AND METHODS

Patients and controls
Cells from 20 CLL patients (10 progressive and 10 non-progressive) and 10 healthy, aged-matched volunteers were included. The clinical characteristics are in Supplementary Table 1S . The study was approved by the local ethics committee. All patient and healthy volunteer samples were obtained with informed consent in keeping with the Helsinki declaration. The diagnostic criteria of CLL have been described previously. 23 Patients were considered to have progressive disease if the following criteria were met: progression during the preceding 3 months in disease-related anemia (hemoglobin o100 g/l), thrombocytopenia (o100 Â 10 9 /l), and/or an increase in spleen/liver/lymph-node size and/or more than a two-fold increase in the blood lymphocyte count. Patients were considered nonprogressive in the absence of these criteria. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll --Hypaque density-gradient centrifugation from heparinized blood.
Production of anti-ROR1 MAbs
Mouse MAbs were generated against 15-to 23-amino-acid-long peptides derived from three different extracellular domains of ROR1 (Supplementary  Table 2S ). High-purity peptides were purchased from Thermo Electron Corporation GmbH (Ulm, Germany). Peptides were conjugated with Keyhole Limpet Hemocyanin (KLH) or bovine serum albumin as described previously. 23 
Immunization protocol
Four BALB/c mice were immunized with each peptide. Immunization was performed five times at 2-week intervals. A 100-mg weight of the conjugated KLH peptide in Freund's complete adjuvant was used for the first immunization. At the subsequent immunizations, 50 mg of the KLH peptide in incomplete Freund's adjuvant were administered. Three days before cell fusion, 20 mg of the KLH peptide, without adjuvant, were injected intravenously. One week prior to the last immunization, blood was collected and antibody titers were determined by ELISA as described below.
ELISA
The wells of a 96-well plate were coated with 100 ml of the peptides (20 mg/ ml) dissolved in phosphate-buffered saline (PBS). The ELISA plate was incubated at 37 1C for 1 h followed by overnight incubation at 4 1C. The plate was washed three times in PBS/Tween buffer for 5 min. A 150-ml volume of bovine serum albumin (2.5%) was added to each well and the plate was incubated at 37 1C for 1.5 h. Wells were then washed three times with PBS/Tween buffer for 5 min. Mouse sera were serially diluted in PBS and 100 ml were added to each well. The plate was incubated at 37 1C for 1.5 h and washed with PBS/Tween three times for 5 min. A rabbit antimouse Ig conjugated with horseradish peroxidase (ARI, Tehran, Iran) was used as the secondary antibody. A 100-ml (1:1000) volume was added and the plate was incubated at 37 1C for 1.5 h and washed three times. After washing 100 ml of tetramethylbenzidine substrate (Sigma, St Louis, MO, USA) was added to each well and the plates were incubated at room temperature in the dark. After 15 min, the reaction was stopped by adding 30 ml of stopping solution (0.16 M sulfuric acid). Optical density was measured at 450 nm using an ELISA reader. Mice with a good antibody response were selected for hybridoma generation.
Hybridoma production
Hybridomas were generated and propagated according to a previously described procedure. 23 Splenocytes from immunized mice were fused with the murine myeloma cell line SP2/0 using polyethylene glycol. Fusion hybrids were selected using HAT medium and the reactivity of the secreted antibody was tested by ELISA.
Antibody purification
MAbs were purified by affinity chromatography. The Hi-Trap Protein G Column (GE Healthcare, Uppsala, Sweden) was used to purify IgG. Briefly, hybridomas were cultured in RPMI with 10% fetal bovine serum and supernatants were collected every 36 h. The supernatants were filtersterilized (0.45 mm) and pH was adjusted to 7.5 by adding 10 Â PBS buffer before loading onto the protein-G column. Elution was performed using 0.1 M glycine (pH 2.7). The pH of the eluted antibodies was adjusted to 7.0 with 1 M Tris buffer (pH 9.0). The eluted antibodies were dialyzed against PBS at pH 7.5. IgM antibodies were purified by a similar procedure using a Sepharose-4B rabbit anti mouse IgM column (ARI).
RNA preparation, cDNA synthesis and IgVH mutation analysis A total of 2 Â 10 6 cells were lysed with 600 ml of RNAzol B reagent (Biosite, Täby, Sweden) for RNA preparation. A 10-mg weight of total RNA was used for cDNA preparation, PCR amplification and IgVH mutation analysis, which were performed as described previously. 23 Cell-surface staining and flow cytometry Staining of CLL cells and PBMCs of healthy donors has been described previously. 25 A total of 1 Â 10 6 cells were washed in PBS and suspended in 100 ml of fluorescence-activated cell sorting buffer (PBS, 0.1% sodium azide and 0.5% fetal bovine serum). A 10-mg weight of the respective anti-ROR1 MAbs was added and incubated at þ 4 1C for 1 h. The cells were washed twice with the fluorescence-activated cell sorting buffer. The secondary antibody (1:100), fluorescein isothiocyanate-conjugated sheep anti-mouse Ig (ARI), was added and incubated at þ 4 1C for 1 h. Blocking was performed by adding 10 ml of 10% mouse serum (DakoCytomation, Glostrup, Denmark) followed by incubation at þ 4 1C for 20 min. phycoerythrin-conjugated anti-CD5 (BD Biosciences, San Jose, CA, USA) and APC-conjugated anti-CD19 (eBioscience, San Diego, CA, USA) were added separately to the cells. The cells were finally washed twice with the fluorescence-activated cell sorting buffer and fixed using 1% paraformaldehyde in PBS. A FACSCalibur flow cytometry (Becton Dickinson (BD), Mountain View, CA, USA) was used. Cells were analyzed using the FlowJo software program (Tree Star Inc., Ashland, OR, USA).
Western blotting
HeLa cells were transiently transfected with an ROR1 gene construct plasmid EN1031_D08 (Origene Technologies, Rockville, MD, USA). A total of 2 Â 10 6 cells were transfected with 10 mg plasmid DNA using the JetPEI transfection reagent (Polyplus-transfection SA, Illkirch, France). Transfected and untransfected cells were harvested after 48 h, and washed twice with 1 Â PBS. A 100-ml volume of lysis buffer containing 1% Triton X-100, 50 mM Tris-HC1 (pH 7.4), 150 mM NaCl, 5 mM EDTA and 1% protease inhibitor cocktail (Sigma) was added to cells. Cells were incubated on ice for 1 h. The protein concentration of the lysate was measured by using the BCA Protein Assay kit (Thermo Scientific, Rockford, IL, USA). A 15-mg weight of the lysate was run on 10% Bis-Tris sodium dodecyl sulfate-PAGE gel (Invitrogen, Carlsbad, CA, USA) at 140 V for 2 h under non-reducing conditions. After electrophoresis, the resolved proteins were transferred onto Immobilon --polyvinylidene difluoride (PVDF) membranes (Millipore Corporation, Bedford, MA, USA) in a mini Transblot cell (Invitrogen). The membranes were blocked for 1.5 h at room temperature with 5% non-fat milk in PBS plus 0.05% Tween-20 (PBS-T). Filters were then incubated with 10 mg of the anti-ROR1 MAb over night at þ 4 1C. After extensive washing with PBS-T, the filters were incubated with peroxidase-conjugated rabbit anti-mouse Igs (DakoCytomation) for 1.5 h at room temperature, followed by washing and development using an ECL chemiluminescence detection system (GE Healthcare).
Poly-(ADP ribose)-polymerase (PARP), cleaved PARP, cleaved caspase-8 and cleaved caspase-9 were analyzed by collecting CLL cells from the apoptosis experiments (see below), washed twice in 1 Â PBS and lysed. A 15-mg weight of the protein was subjected to western blotting under non-reducing conditions. Filters were incubated with a mouse anti-PARP MAb, a rabbit MAb against cleaved caspase-8 (p 43/41 and p18) and a ROR1---a potential novel therapeutic target AH Daneshmanesh et al rabbit polyclonal antibody against cleaved caspase-9 (p37) (1:1000) (Cell Signaling Technology, Danvers, MA, USA) overnight at þ 4 1C, and subsequently with a peroxidase-conjugated rabbit anti-mouse antibody and a peroxidase-conjugated goat anti-rabbit antibody, respectively (DakoCytomation).
Apoptosis (Annexin-V) assay
A total of 2 Â 10 6 target cells (CLL cells or PBMCs of healthy donors) were incubated with 10 mg/ml of the ROR1 mouse MAbs, the murine anti-CD20 MAb clone LT-20 (IgG) (EXBIO Praha, a.s., Vestec, Czech Republic), the chimeric anti-CD20 antibody (rituximab) (Roche, Basel, Switzerland) or relevant isotype controls in 1 ml of serum-free medium (CTL-010; Cellular Technology Ltd, Shaker Heights, OH, USA). Dose --response curves were generated for three of antibodies (1D8, 4A7 and 4C10). A 10-mg/ml concentration was found to be an optimal, on the steep slope of the curve before plateau (Supplementary Figure 1S) . After 18 h of incubation at 37 1C in humidified air with 5% CO 2 , cells were harvested, washed twice with 1 Â PBS and resuspended in 100 ml of 1 Â binding buffer at a concentration of 1 Â 10 6 cells/ml. A 5-ml volume of fluorescein isothiocyanate-conjugated Annexin-V and propidium iodide (PI) (BD Biosciences) was added to the cells, vortexed and incubated at room temperature in the dark for 15 min. A 100-ml volume of 1 Â binding buffer was added to the cells, which then were analyzed by flow cytometry (FACSCalibur). For calculation of the percentage of apoptotic cells, we used the Annexin-
MTT cytotoxicity assay MTT assay was used to determine cell viability after incubation with the MAbs as described previously. 26 Briefly, 1 Â 10 5 CLL cells were incubated in 0.5 ml of RPMI-1640 (without phenol red) (Invitrogen) containing 10% fetal bovine serum in triplicates. Anti-ROR1 MAbs as well as isotype controls were added from 1 --20 mg/ml. Untreated cells and medium without cells were used as controls. Cells were incubated for 18 h. A 100-ml volume of medium was removed and 100 ml of MTT (5 mg/ml) (Sigma) in PBS was added and the cells were incubated for a further 4 h at room temperature. The formed formazan crystals were dissolved in 300 ml of MTT solvent (4 mM HCl, 0.1% NP-40 in isopropanol), shaken for 15 min, and absorbance was measured at 595 and 655 nm. Cytotoxicity was calculated as follows: % cytotoxicity ¼ (1À(A595ÀA655 of treated samples/A595ÀA655 of controls)) Â 100.
Cross-linking of ROR1 MAbs for induction of apoptosis CLL cells were dispensed in 50 ml of serum-free medium (CTL-010) (7000 cells per well) in a 96-well plate. ROR1 MAbs or LT-20 (murine anti-CD20) (MAbs), and the F(ab 0 ) 2 fragments of goat anti-Fc mouse IgG and IgM used for cross-linking of the primary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), were added at four times the final concentration, 8 and 24 mg/ml, respectively. Cells were incubated at 37 1C under 5% CO 2 in humidified air for 24 h. Apoptosis was assayed as above.
Complement-dependent cytotoxicity CDC was performed as described previously. 27 In brief, 5 Â 10 4 PBMCs from CLL patients (n ¼ 20) or healthy donors (n ¼ 4) were seeded in 96-well, flatbottom cell culture plates in 200 ml of RPMI-1640 with 10% fetal calf serum and incubated with the ROR1 MAbs for 30 min at room temperature. Control MAbs included rituximab (Roche), ofatumumab (GlaxoSmithKline, London, UK) and alemtuzumab (Genzyme Inc., Boston, MA, USA). The cells were then washed and resuspended in 200 ml of medium with or without 20% fresh normal human serum as a source of complement and incubated for 1 h at 37 1C. Cell death (PI) was measured as above.
Statistical analysis
The GraphPad Prism 5 software was used. Correlation between groups was analyzed by nonparametric Mann --Whitney U-test. Correlations between apoptosis and the different MAbs were tested by analysis of variance Bonferroni's multiple comparison test.
RESULTS
Twenty-one stable hybridomas were generated against peptides derived from the Ig, CRD and KNG regions of the extracellular part of ROR1. Five hybridomas were selected based on specific reactivity with the corresponding peptide (ELISA) (Supplementary Table 2S ). All five MAbs recognized a band of 100 --105 kDA corresponding to the predicted size of ROR1 (Figure 1 ). One MAb, anti-Ig (3B8) (IgM), was against the Ig domain (23aa). Two MAbs, anti-CRD (1C11) (IgM) and anti-CRD (1D8) (IgG1), were against the CRD (15aa) domain. Two MAbs, anti-KNG (4C10) (IgM) and anti-KNG (4A7) (IgG1), were against the KNG domain (19aa).
Cell-surface staining for ROR1 Each of the ROR1 MAbs was tested for surface staining. CLL cells were stained by the different MAbs (Figures 2a and 3a , and Supplementary Figure 3S) but not the B-cell population of PBMCs of healthy donors (double staining) (Figures 2b and 3a , and Supplementary Figure 2S) . The staining frequency for each ROR1 MAb of CLL cells was similar to or exceeded that of CD19 (Figure 2a) .
We next confirmed that staining of PBMCs was specifically related to CLL cells using triple-staining experiments with CD19 and CD5 (Figure 3a) . Not all CLL cells were stained by each of the ROR1 MAbs. The number of ROR1-positive, and CD5 þ and CD19 þ cells (leukemic cells), ranged from 72 to 99%. There was a slight difference in the frequency of cells stained by the different clones.
þ cells from CLL patients or healthy donors (o3%) were stained by any of the anti-ROR1 MAbs (data not shown).
We then compared the proportion of ROR1-positive CLL cells in triple-staining experiments using CD19 and CD5 in patients with non-progressive and progressive disease (Figures 3b and  Supplementary Table 3S) . A significantly higher proportion of ROR1-positive CLL cells assessed by all the ROR1 MAbs was noted for patients with progressive disease as compared with nonprogressive disease (Figure 3b ). The frequency of ROR1-positive cells was also significantly higher (Po0.05---Po0.01) in patients with unmutated IgVH genes as compared with those with mutated IgVH stained with ROR1 MAbs of clones 3B8 (Ig), 1C11 (CRD) and 4A7 (KNG), but not by the two others (data not shown). No statistically significant correlation comparing the mean fluorescence intensity values of progressive and non-progressive patients could be seen. It should be noted that all patients in Figure 1 . Western blot analyses of ROR1-transfected ( þ ) and untransfected (À) HeLa cells using a complete ROR1 construct (see Materials and Methods) and the five different ROR1 MAbs. A band at 100 --105 kDa was observed in ROR-1-transfected but not in untransfected cells corresponding to the predicted size of ROR1.
the non-progressive group were untreated, whereas in the progressive group 8/10 had previously received therapy.
Induction of apoptosis of the ROR1 MAbs alone
The target cells in an apoptosis assay (Annexin-V þ /PI þ ) (serumfree medium) in the absence of a complement or added immune effector cells were isolated PBMCs of CLL patients (n ¼ 20) and healthy donors (n ¼ 8). PBMCs of CLL patients consisted of an average of 87 ± 2% ROR1 þ cells (range: 76 --98%) (Figure 3a) . The time kinetics of apoptosis during a 24-h incubation period was evaluated in two patients using the two anti-ROR1 IgG1 MAbs directed against the CRD and KNG domains, as well as rituximab (chimeric anti-CD20). Based on the results, 18 h of incubation was selected for the subsequent experiments as a high degree of spontaneous cell death of the CLL cells occurred subsequently, which obscured antibody-induced apoptosis, which is in line with previous reports on in vitro spontaneous apoptosis of CLL cells. 28 At 18 h, less than 20% of CLL cells had undergone spontaneous apoptosis (Figure 4) , representing an acceptable background.
All ROR1 MAbs alone induced, to a varying degree, apoptosis of the CLL cells of all patients (Figure 4 ). The differences comparing CLL cells with no antibody or isotype controls were statistically highly significant (Po0.0001). Apoptosis of normal PBMCs was not induced by any of the ROR1 MAbs (Figure 4 ). There was no significant difference between the two anti-CRD ROR1 MAbs, one of the IgM (1C11) and one of the IgG1 (1D8) isotype ( Figure 4 and Table 1 ). These two MAbs together with one of the anti-KNG (4C10) (IgM) MAb were the best to induce apoptosis (Table 1) . Moreover, these three MAbs (1C11, 1D8, 4C10) were also significantly more effective in inducing apoptosis of CLL cells than the murine (LT-20) or the chimeric (rituximab) anti-CD20 MAb (Po0.0001) (Figure 4 and Table 1 ). The two other ROR1 MAbs, 3B8 (Ig) and 4A7 (KNG), induced CLL cell apoptosis to a better or similar degree as LT-20 and rituximab ( Figure 4 and Table 1 ). There was no clear relation between the frequency of ROR1-positive CLL cells and apoptosis (data not shown). MTT cytotoxicity assay was also applied to confirm the apoptotic effects of our anti-ROR1 MAbs. The result of a representative experiment is shown in Supplementary Figure 4S .
One of our ROR1 MAbs (4A7) (IgG1) (Figures 4, 6 and 7 ) alone was also tested and found to induce apoptosis of the ROR1 þ CLL cell line EHEB 29 (data not shown). As additional tests for apoptosis, western blot analysis for cleaved PARP, caspase-8 and caspase-9 proteins were performed using protein lysates of CLL cells from the apoptosis experiments (see above). All five anti-ROR1 MAbs induced a PARP cleavage product of 85 kDa ( Figure 5 ), cleaved caspase-8 (p43/41, 43/41 kDa and p18, 18 kDa) and cleaved caspase-9 (37 kDa) (Supplementary Figure 4S) . Rituximab also induced a weak 85 kDa cleaved PARP band as has been described. 27 Complement-dependent cytotoxicity A 1-h CDC assay was applied using normal human serum as complement to analyze the CDC capacity of the ROR1 MAbs on CLL cells and normal PBMC. Clinically approved CLL MAbs (rituximab, ofatumumab and alemtuzumab) were used for comparison ( Figure 6) .
A significantly higher cytotoxicity with complement than without was observed for the two IgG1 ROR1 MAbs (1D8 (CRD) and 4A7 (KNG)) (Po0.05). Rituximab used at the same concentration was also effective in CDC as described previously. 27 The difference compared with 1D8 was statistically not significant, whereas the effect of 4A7 was slightly lower than that of rituximab (Po0.05). Ofatumumab and alemtuzumab, both of which are known to be particularly effective in inducing CDC of CLL cells, 27, 30 were the most effective. ROR1 MAbs as well as rituximab did not induce lysis of normal PBMCs in the presence of complement. However, a significant complement lysis (Po0.001) of normal PBMCs was induced by ofatumumab and alemtuzumab (data not shown).
Cross-linking of ROR1 MAb and apoptosis We also applied cross-linking of the ROR1 MAbs using the F(ab 0 ) 2 fragment of antibodies against the Fc part of mouse IgG and IgM, respectively. Cross-linking mimicks on target cells the effect of multiple MAb molecules binding to FcgR on effector cells. Significantly enhanced cytotoxicity was observed with crosslinking of all ROR1 MAbs except for 1D8 (CRD) and 4C10 (KNG) (Figure 7 ). However, it should be noted that these two antibodies alone induced the highest cytotoxicity, which was not further enhanced by cross-linking. Additional cytotoxicity by cross-linking was not noted for the isotype control antibodies or for murine anti-CD20 (Figure 7) . Figure 3 . The frequency of apoptotic cells (Annexin-V þ /PI þ ) induced by ROR1 MAbs was significantly higher than isotope controls (Po0.0001). The anti-ROR1 MAbs 1C11, 1D8 and 4C10 induced significantly higher frequencies of apoptotic cells than the anti-CD20 control MAbs (Po0.001) ( Table 1 ). There was no statistically significant difference in the frequency of apoptotic cells comparing Ig3B8 and KNG4A7, respectively, and the anti-CD20 MAb (Table 1) .
ADCC activity
The CLL cell line (EHEB) was also used to test killing activity by antibody-dependent cellular cytotoxicity (ADCC) using PBMCs from normal donors as effector cells, and the anti-ROR1 MAb KNG 4A7 (IgG1) and was found to induce a significant cell death (data not shown). Moreover, using PBMCs from CLL patients as target cells and effector cells from normal donors, the anti-ROR1 MAb KNG 4A7 could also induce significant killing by ADCC of leukemic cells (Supplementary Figure 5S) .
DISCUSSION
Targeting RTKs such as epidermal growth factor receptor or Her2/ neu using MAbs has been an effective approach to therapy in various malignancies. 9, 10 Our previous study as well as those of others 22 --24 have demonstrated that in all CLL patients the majority of the leukemic cells express the RTK ROR1. Recently, published results indicate that ROR1 is also expressed in other Bcell malignancies. 31, 32 ROR1 has been shown to be constitutively phosphorylated in CLL 33 and silencing of ROR1 with small interfering RNA induced apoptosis of the CLL cells.
34 ROR1 is not expressed on normal adult lymphoid and non-lymphoid cells, 22, 24 but to some extent during the early stage of normal Bcell development and adipose tissue. 32 These findings may suggest that ROR1 might be an attractive structure for targeted therapy.
In this study, a panel of mouse MAbs was produced with the aim to explore functionally ROR1 epitopes for subsequent CDC for 1D8 compared with rituximab was statistically not significant, whereas rituximab was slightly more effective than 4A7 in CDC (Po0.05). generation of human ROR1 MAbs for clinical trials. To address this, we performed cell-surface analyses for ROR1 and tested the ROR1 MAbs in five functional assays, that is, direct induction of apoptosis (Annexin-V, MTT), cross-linking of the surface-bound ROR1 MAbs as well as in CDC and ADCC, and compared with approved MAbs for CLL therapy. The antibodies were raised against peptides derived of the natural sequence of the extracellular Ig (23aa), CRD (15aa) and KNG (19aa) domains of ROR1, respectively. These epitopes should be devoid of N-or O-linked glycosylations. 35 The varying staining pattern of individual patients by the different ROR1 MAbs may suggest a structural heterogeneity in the ROR1 expression. Antibodies alone against the CRD and KNG regions had a high cytotoxic capability. This is an interesting observation as the CRD and KNG regions are presumed to contain Wnt-family and non-Wnt-ligand binding modules involved in a variety of cellular responses. 12, 13, 36, 37 Induction of direct apoptosis was confirmed by expression of Annexin-V, MTT assay and cleavage of PARP, as well as caspase-8 and caspase-9 proteins, covering both the extrinsic (receptor mediated) and intrinsic (mitochondrial mediated) apoptosis pathways. 38, 39 Apoptosis was most likely not induced by immune effector cells (ADCC) as about 90% of the PBMCs were CD19 þ
CD5
þ cells and very few natural killer cells/monocytes (3 --4%) were present (data not shown). In vitro, an excess of 10 --50 times of effector cells compared with target cells is required to induce a detectable ADCC. 40 Two of our IgG1 ROR1 MAbs could also mediate complement lysis. The CH 2 domain of the IgG molecule is highly conserved among species, 41 and mouse as well as human antibodies might be comparable with regard to complement activation.
It is obvious using our technology that all leukemic cells could not be detected to express ROR1. Whether this is due to low surface expression or a truly ROR1-negative leukemic cell subpopulation in some patients could not be ruled out at present. However, it is known that all CLL cells do not express a detectable molecule identified by a given MAb. 42, 43 A high density of RTK on tumor cells is related to high proliferative potential and/or survival advantage of the tumor cells, as well as an indicator of poor clinical prognosis. 8, 35 In keeping with these observations, patients with progressive disease had a higher frequency of ROR1-positive CLL cells than those with non-progressive disease. It should however be noted that 8/10 patients in the progressive group had previously received treatment, whereas none in the non-progressive group. Whether treatment could explain this difference requires an extended patient material. However, in untreated individual patients, when the disease changed from a non-progressive to progressive phase, the frequency of ROR1 þ cells increased (data to be published). Our results are in contrast to those of others showing no difference comparing patients with progressive and non-progressive disease using a polyclonal goat anti-human ROR1 antibody. 22, 44 The enhanced effect by cross-linking of the ROR1 antibodies has also been observed for antibodies against CD20 and RTKs. 45, 46 Cross-linking of cell surface-bound antibodies may mirror crosslinking induced by Fcg receptors expressed by effector cells participating in ADCC. 45 One of our anti-ROR1 (KNG 4A7) (IgG1) also induced a significant killing activity by ADCC.
MAbs alone against the CRD and KNG regions were highly effective in inducing apoptosis of the leukemic cells. The CRD region might be a ligand-binding module for Wnt proteins and the KNG domain might also be involved in Wnt and non-Wnt ligand interactions. 12, 13, 18, 37 Epitope-dependent cytotoxicity has been reported for antibodies against CD20 and other RTKs. 8, 47, 48 Three of our ROR1 MAbs appeared to be significantly more effective in inducing apoptosis than the murine or the chimeric anti-CD20 MAbs. Rituximab alone has been shown to induce a low degree of apoptosis 49 as also confirmed by our study, but crosslinking of rituximab, the presence of complement or effector cells was necessary to induce a high degree of cell death. 48, 49 The difference in the apoptosis-inducing capability of the anti-ROR1 MAbs may also be influenced by other factors than their binding region. The MAbs were of different isotypes, IgM or IgG, and had presumably different binding affinities, which was not examined. However, the IgM and IgG anti-CRD MAb appeared to be equally effective in inducing apoptosis. There was also a variation between patients in ROR1 expression, which may also explain the difference in apoptosis induced by the individual antibodies, although a clear relation between ROR1 expression ((frequency and density) (mean fluorescence intensity)) and apoptosis could not be established (data not shown), which similarly has been reported for MAbs against CD20 and other RTKs. 46, 50 In summary, we describe the generation, staining pattern and cytotoxicity of a panel of mouse MAbs against ROR1. The identified functional epitopes of ROR1 in CLL will be further used in the development of human antibodies against ROR1 for clinical trials. The efficacy of our MAbs are in contrast to those produced by Yang et al. 51 indicating that their MAbs might be more suitable as conjugates or chimeric antigen receptors. Their antibodies alone did not induce apoptosis, or mediated CDC and a low ADCC activity. ROR1 targeted therapy may not only include MAbs but also small RTK inhibitor molecules (own unpublished data) as well as T cells modified to express an ROR1-specific chimeric antigen receptors. 32 
